Treatment of immunodeficiency with interleukin-2: initial exploration

J Biol Response Mod. 1984 Oct;3(5):483-90.

Abstract

Fifteen patients with acquired immunodeficiency syndrome (AIDS), lymphoma and immunodeficiency, or severe combined immunodeficiency were treated with highly purified interleukin-2 (IL-2) prepared from human lymphocytes. All patients showed a defect in mitogen-induced T cell proliferation which was partially corrected when IL-2 was added in vitro. IL-2 was administered subcutaneously by daily injection or continuous infusion. The maximum daily dose was 20,000 U/m2, the maximum total dose 855,000 U/m2, and the maximum period of treatment 77 days. An increase in the platelet count was seen in one patient with AIDS, a decrease in the serum level of a monoclonal immunoglobulin in another patient with AIDS, and a minor tumor response in a patient with diffuse histiocytic lymphoma. As no toxicity was observed, further study of IL-2 in the treatment of human immunodeficiency is indicated.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / therapy*
  • Adult
  • Child, Preschool
  • Drug Evaluation
  • Female
  • Humans
  • Immunotherapy / adverse effects
  • Interleukin-2 / administration & dosage*
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Mitogens / pharmacology
  • T-Lymphocytes / immunology

Substances

  • Interleukin-2
  • Mitogens